Abstract IA011: Engineered IL-12 delivery to the tumor matrix to achieve enhanced efficacy and safety in multiple advanced tumors

作者
Jun Ishihara
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:22 (12_Supplement): IA011-IA011
标识
DOI:10.1158/1535-7163.targ-23-ia011
摘要

Abstract Background. Our goal is to create an effective and novel immunotherapy against multiple solid tumors with minimal toxicity. IL-12 is an “ideal” immune-activator, capable of activating both innate and acquired immune response. We tested more than 20 reported pro-inflammatory cytokines, and found IL-12 shows the most potent anti-tumor activity. Peripheral toxicity limits the use of systemic IL-12 therapy in the clinic. We have hypothesized that the tumor-specific drug delivery system would improve IL-12 immunotherapies. We took original approaches of protein engineering. Methods. We developed technologies to turn the tumor collagen into a drug reservoir after intravenous injections. The recombinant fusion of IL-12 to a collagen binding domain (CBD) derived from the VWF A3 domain allows for targeted IL-12 delivery into the tumor stroma. Here, we evaluated the pharmacology, safety, efficacy and the effects of CBD-IL-12 to the tumor microenvironment. Results. Intravenously-injected CBD proteins preferentially localized to the tumor, but not in other organs in mice. Single intravenous injection of CBD-IL-12 (recombinant fusion protein) eradicated most EMT6 breast cold tumors. CBD-IL-12-treated mice that were tumor-free developed systemic immunological memory, as 12 mice out of 13 rejected rechallenge with the breast tumor cells in their contralateral mammary fat pad. Single intravenous injection of CBD-IL-12 induced 67% complete remission of established B16F10 tumors. CBD fusion to IL-12 reduced the systemic toxicity, such as 50% reduction of hepatotoxicity markers and cytokine storm. CBD-IL-12 treatment increased intratumoral cytokine and immune cell numbers. In short, this tumor collagen-targeting approach improves both safety and efficacy of IL-12. We showed that the CBD can target multiple solid tumor types, because the CBD exploits the abnormality of tumor vasculature-specific pathological structure (e.g. leakiness and exposure of collagen to the bloodstream). So far, we have shown that CBD-IL-12 has significant anti-tumor efficacy in breast, lung, ovarian, liver, colon, prostate, melanoma, head and neck, pancreatic cancers and melanoma, sarcoma, and glioblastoma in syngeneic mouse models. CBD-IL-12 is effective in cold, advanced, spontaneous tumors, low-mutation burden tumors, and prevents metastasis and recurrence. CBD-IL-12 stimulated antigen-presenting cells and T cells. Also, humanized mice treated with humanized CBD-IL-12 show great anti-tumor effects in patient-derived lung and ovarian tumors. Humanized CBD-IL-12 was tested in dogs, and showed great tolerability at the therapeutic dose. Human CBD-IL-12 molecule was successfully manufactured in a clinical-grade. Conclusions. Intravenously injected CBD–IL-12 is effective to multiple difficult, immunologically cold tumors with low mutation burdens. Collagen is an attractive target because abnormally high expression of collagen is a shared nature of tumors, regardless of tumor types and patients. VWF A3 domain naturally exists in our body, minimizing the risk of immunogenicity. Citation Format: Jun Ishihara. Engineered IL-12 delivery to the tumor matrix to achieve enhanced efficacy and safety in multiple advanced tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr IA011.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Yanzhi完成签到,获得积分10
1秒前
3秒前
4秒前
玖月完成签到 ,获得积分0
4秒前
Yexin完成签到,获得积分10
6秒前
6秒前
麒麟发布了新的文献求助10
8秒前
LSQ47完成签到,获得积分10
8秒前
qinyaopanda发布了新的文献求助10
11秒前
风雨晴鸿完成签到 ,获得积分10
12秒前
科研通AI6.2的应助被son采纳,获得10
13秒前
Island完成签到 ,获得积分10
13秒前
机智的访云完成签到,获得积分10
13秒前
众行绘研完成签到 ,获得积分10
13秒前
拂晓完成签到,获得积分10
15秒前
义气绍辉完成签到,获得积分10
15秒前
高兴薯片完成签到 ,获得积分10
17秒前
青云完成签到,获得积分10
17秒前
pmsl完成签到,获得积分10
19秒前
清爽的人龙完成签到 ,获得积分10
20秒前
糖诗完成签到 ,获得积分10
20秒前
饿哭了塞完成签到 ,获得积分10
21秒前
无心的千雁完成签到,获得积分10
21秒前
灵巧小夏完成签到,获得积分10
21秒前
汪欣怡完成签到 ,获得积分10
22秒前
叶子完成签到 ,获得积分10
22秒前
zoe完成签到,获得积分10
23秒前
breif完成签到 ,获得积分10
24秒前
ZRJ完成签到 ,获得积分10
24秒前
123完成签到,获得积分10
25秒前
麒麟完成签到,获得积分10
27秒前
笛卡尔的情书完成签到 ,获得积分10
27秒前
后浪完成签到 ,获得积分10
28秒前
yy完成签到,获得积分10
31秒前
31秒前
儒雅的蜜粉完成签到,获得积分10
32秒前
勤奋日光完成签到,获得积分10
33秒前
清淮完成签到 ,获得积分10
34秒前
夏梓硕完成签到,获得积分10
35秒前
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173350
求助须知:如何正确求助?哪些是违规求助? 9565632
关于积分的说明 21780706
捐赠科研通 7767517
什么是DOI,文献DOI怎么找? 3431557
关于科研通互助平台的介绍 2555846
邀请新用户注册赠送积分活动 2476749